TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: As such, BV revealed safety and effectiveness, and was subsequently approved in the treatment of anaplastic large cell lymphoma (ALCL), systemic or cutaneous, CD30+ peripheral T cell lymphoma (PTCL), and CD30+ mycosis fungoides (MF).